Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Teste de desafio de alérgenos de IRL201104 em rinite alérgica sazonal

17 de setembro de 2026 atualizado por: Revolo Biotherapeutics

Fase 2a, Randomizado, Duplo-Cego, Controlado por Placebo, Projeto Paralelo, Teste de Desafio de Alérgeno de 6 Doses Repetidas de IRL201104 em Participantes Adultos com Rinite Alérgica Sazonal.

The purpose of this allergen challenge study is to assess the efficacy of IRL201104 compared with placebo in adult participants with seasonal allergic rhinitis.

Visão geral do estudo

Status

Concluído

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

63

Estágio

  • Fase 2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • London, Reino Unido
        • Hammersmith Medicines Research
      • London, Reino Unido
        • King's College London

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos a 65 anos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Male or female, 18 to 65 years old, inclusive, at time of signing the informed consent form (ICF).

  2. Body mass index within the range 19 to 30 kg/m2.

  3. A clinical history of grass pollen-induced allergic rhinitis for at least 2 years with peak symptoms in May, June, or July.

  4. A clinical history of moderate to severe rhinitis symptoms interfering with usual daily activities or with sleep as defined according to the ARIA classification of rhinitis (Bousquet, Khaltaev et al 2008)

  5. A clinical history of rhinitis for at least 2 years requiring treatment with either antihistamines or nasal corticosteroids during the grass pollen season.

  6. Positive skin prick test response, defined as wheal diameter greater than or equal to 5 mm, to Phleum pratense.

  7. Positive specific IgE, defined as greater than or equal to IgE class 2 (0.7 kU/L), against Phleum pratense.

  8. A positive response to the nasal allergen challenge with Phleum pratense, defined as an increase in TNSS greater than or equal to 5 points.

  9. Agree to follow the contraception requirements of the trial as described in Appendix 7.

    Female participants must agree to use highly effective contraception as described in Appendix 7, or must be of non-childbearing potential. A woman is considered to be of non-childbearing potential if she meets one of the following criteria:

    1. post-menopausal (amenorrhea for at least 12 months, and follicle-stimulating hormone [FSH] tests at screening confirms post-menopausal status)
    2. has no uterus, ovaries or fallopian tubes. c. documentation of non-childbearing potential from a reproductive specialist.
  10. The ability to give informed consent and comply with study procedures.

  11. Venous access as appropriate for IV dosing, as judged by the investigator or delegate.

Exclusion Criteria:

  1. A prebronchodilator forced expiry volume in 1 second (FEV1) less than 70% of the predicted value at the screening baseline visit.
  2. Clinical history of persistent asthma requiring regular inhaled corticosteroids for > 4 weeks per year outside of the grass pollen season.
  3. Clinical history of moderate - severe allergic rhinitis, according to the ARIA classification, caused by a perennial allergen to which the participant is regularly exposed.
  4. Clinical history of moderate-severe allergic rhinitis, according to the ARIA classification, caused by tree pollen (those with mild intermittent symptoms not requiring regular treatment may be included).
  5. History of emergency visit or hospital admission for asthma in the previous 12 months.
  6. History of chronic obstructive pulmonary disease.
  7. History of significant recurrent acute sinusitis, defined as 2 episodes per year for the last 2 years, all of which required antibiotic treatment.
  8. History of chronic sinusitis, defined as sinus symptoms lasting greater than 12 weeks that includes 2 or more major factors or 1 major factor and 2 minor factors. Major factors are defined as facial pain or pressure, nasal obstruction or blockage, nasal discharge or purulence or discolored postnasal discharge, purulence in nasal cavity, or impaired or loss of smell. Minor factors are defined as headache, fever, halitosis, fatigue, dental pain, cough, ear pain, pressure, or fullness.
  9. History of systemic disease affecting the immune system such as autoimmune diseases, immune complex disease, or immunodeficiency.
  10. At randomization, current symptoms of, or treatment for, upper respiratory tract infection, acute sinusitis, acute otitis media, or other relevant infectious process; serous otitis media is not an exclusion criterion. Participants may be re-evaluated for eligibility after symptoms resolve.
  11. Active malignancy at randomization.
  12. Any tobacco smoking within the last 6 months or a history of greater than or equal to 10 pack years.
  13. Previous treatment by immunotherapy with grass pollen allergen within the previous 5 years.
  14. History of bleeding disorders or treatment with anticoagulation therapy.
  15. History of anti-IgE monoclonal antibody treatment.
  16. Ongoing systemic immunosuppressive treatment.
  17. History of intolerance to the study therapy, rescue medications, or their excipients.
  18. Pregnant or lactating women. For women of childbearing potential, a positive serum or urine pregnancy test.
  19. The use of any investigational drug within 30 days of the screening visit.
  20. The presence of any medical condition that the investigator deems incompatible with participation in the study.
  21. Moderate or severe renal impairment (eGFR <60 mL/min/1.73 m2) or end stage renal disease.

23. Known or suspected immunosuppression, including history of invasive opportunistic infections (eg, history of or active tuberculosis, non-tuberculous mycobacterial infections, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency, or prolonged infections suggesting an immunocompromised status, as judged by the investigator. 24. Clinically relevant abnormal history, physical findings, ECG, or laboratory values at the pre-study screening assessment that could interfere with the objectives of the study or the safety of the volunteer. 25. Clinical contraindication to intradermal challenge (IDC), skin prick test (SPT), skin prick titration (SPT), or nasal allergen challenge (NAC), to include:

  1. Previous anaphylactic reaction to grass pollen or extract excipients
  2. Acute inflammation of the nose or paranasal sinuses
  3. Severe and uncontrolled bronchial asthma or chronic obstructive pulmonary disease
  4. Systemic immunotherapy
  5. A generalised dermatological condition rendering it impracticable to perform SPT or IDC on unaffected skin.
  6. Severe dermatographism
  7. Unable to cease antihistamines/other interfering drugs (i.e. antidepressants)
  8. Concomitant use of beta-blockers

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm 1: IRL201104

IRL201104 IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70

lyophilised powder for reconstitution for IV dosing

Comparador de Placebo: Arm 2: Placebo

Placebo IV on Day 1, Day 14, Day 28, Day 42, Day 56, Day 70

Matching placebo for IRL201104

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
The mean diameter of the Intradermal Challenge (IDC) Late Phase Response (LPR) on Day 84 measured 8 hours post-challenge after 10 weeks of treatment with IRL201104 compared with placebo.
Prazo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
The largest diameter (mm) of the IDC Early Phase Response (EPR) at 30 minutes after 10 weeks of treatment with IRL201104 compared with placebo
Prazo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
Skin prick test EPR endpoint titration of Grass Soluprick after 10 weeks of treatment with IRL201104 compared with placebo.
Prazo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
The weighted average of the TNSS per hour following NAC after challenge on Day 1 and day 84 of treatment with IRL201104 compared with placebo.
Prazo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
Percent change in peak nasal inspiratory flow (PNIF) after the NAC on day 1 and day 84 of treatment with IRL201104 compared with placebo.
Prazo: Day 84

An analysis of covariance (ANCOVA) will be performed

Day 84
Concentration of IRL20114 levels.
Prazo: Day 56

IRL201104 plasma levels will be summarized for each blood sample draw timepoint

Day 56
Vital Signs: Blood pressure
Prazo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Vital Signs: Pulse rate
Prazo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Vital Signs: oral body temperature
Prazo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Vital Signs: respiration rate
Prazo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Treatment Emergent Adverse Events
Prazo: Day 84

Summary statistics, by and across randomized treatment group

Day 84
Incidence of treatment-emergent antidrug antibody (ADA) responses
Prazo: Day 84

Tabulated and presented as the number and percentage of participants exhibiting the response within each treatment group

Day 84
Safety Laboratory: Biochemistry
Prazo: Day 84

Glucose, liver function tests, urea, and electrolytes will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84.

Day 84
Safety Laboratory: Haematology
Prazo: Day 84

Full blood count variables will be analysed by summary statistics, by and across randomized treatment group with data from Day 1, 56 and 84.

Day 84

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Anoshie Ratnayake, MD, Revolo Biotherapeutics

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

4 de novembro de 2021

Conclusão Primária (Real)

27 de março de 2023

Conclusão do estudo (Real)

27 de março de 2023

Datas de inscrição no estudo

Enviado pela primeira vez

30 de setembro de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

18 de outubro de 2021

Primeira postagem (Real)

28 de outubro de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

21 de setembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • RVLO 121-05

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .